# The convenience gap is closing. Amgen competitors noticed. - Date: 2026-04-06 - Category: Biotech & Life Sciences Amgen fixed the one thing keeping competitors in the race: a subcutaneous version of its blockbuster thyroid eye disease drug Tepezza. But the window it bought may be shorter than it looks. ---